XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales $ 3,855 $ 4,080 $ 10,831 $ 11,365  
Selling, general and administrative 2,633 2,731 7,835 7,952  
Research and development 4,234 5,862 11,903 13,354  
Other current assets 47,557   47,557   $ 38,782
Accrued and other current liabilities 16,186   16,186   15,694
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 593 376 1,362 1,061  
Cost of sales 84 82 253 245  
Selling, general and administrative 31 39 103 121  
Research and development 3 19 31 57  
Other current assets 436   436   424
Accrued and other current liabilities 4   4   $ 713
Upfront payments recognized as revenue     150    
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 379 337 1,061 947  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 214 $ 39 301 $ 114  
Upfront payments recognized as revenue 150        
AstraZeneca | Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payments recognized as revenue $ 50   $ 50